Open Access
ARTICLE IN FRENCH
Ollo Roland Somé1,*, Abdoul Halim Bagué2, Damien Konkobo1, Dieudonné Hien3, Adama Dembélé3, GL Hermann Bélemlilga1, Valentin Konségré4, Nayi Zongo5
Oncologie, Vol.24, No.2, pp. 173-184, 2022, DOI:10.32604/oncologie.2022.021250
Abstract Introduction: Breast cancer management in Sub-Saharian Africa, is faced with diagnosis and treatment challenges. This study aims to describe, breast cancers epidemiology in Bobo-Dioulasso, Burkina Faso. Patients
and method: A retrospective cohort study was performed from July 01, 2015 to December 31, 2021 in the Souro
Sanou university teaching hospital. Histologically confirmed breast cancer patients were included. Clinical aspect,
treatment features and outcome data were collected and analyzed. Results: In study time, eight male’s cases (2%)
360 female’s cases among 368 breast cancers cases were included. The mean age was 46.6 ± 12.1 years, ranging
from 15 to 90. The… More >
Open Access
REVIEW
Amir Imran Faisal Hamdi, Johnson Stanslas*
Oncologie, Vol.24, No.2, pp. 185-194, 2022, DOI:10.32604/oncologie.2022.023629
Abstract KRAS mutations are among the most common oncogenic abnormalities in cancer. Until recently, drug discovery pursuing KRAS did not produce therapeutic benefits for patients. Specific KRAS inhibitors, such as sotorasib and adagrasib, which bind covalently to codon 12 of substituted glycine to cysteine residue of the protein (G12C), have been approved by the FDA recently for the treatment of lung cancers. Binding of these drugs to the protein inhibits the activation of the GDP-bound inactive state to the GTP-bound active state. Phase 1/2 trials have shown potential anti-tumor activity, particularly in patients with previously treated non-small cell lung cancer. Acquired… More >
Open Access
REVIEW
Dariimaa Ganbat1,2, Bat-Erdene Jugder3, Lkhamaa Ganbat4, Miki Tomoeda5, Erdenetsogt Dungubat2,6, Ambaga Miyegombo7, Gantsetseg Garmaa8, Yoshihisa Takahashi6, Ryuji Fukuzawa6, Ichiro Mori6, Takayuki Shiomi6, Akinori Nakata9, Yasuhiko Tomita6,*
Oncologie, Vol.24, No.2, pp. 195-225, 2022, DOI:10.32604/oncologie.2022.022299
Abstract Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating
from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited
therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels.
Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered
as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical
outcomes and pharmacological… More >
Open Access
REVIEW
Robabeh Faghani Baladehi1,2, Mohammad Yousef Memar1, Abolfazl Jafari Sales3, Ahad Bazmani1,4, Javid Sadri Nahand1,5,6, Parisa Shiri Aghbash2,7, Hossein Bannazadeh Baghi1,2,7,*
Oncologie, Vol.24, No.2, pp. 227-245, 2022, DOI:10.32604/oncologie.2022.020648
Abstract The ability of host cells to activate apoptosis is perhaps the most potent weapon for helping cells eliminate viruses.
Human papillomaviruses (HPV) activate several pathways, enabling the infected cells to avoid extrinsic and
intrinsic apoptosis pathways. The incapacity of prostatic epithelial cells to induce apoptosis leads to the invasive
development of prostate cancer. For the pathogenesis of prostate cancer, several risk factors have been reported;
for example, some viruses and infectious diseases have been proposed as causative agents for their relation to
prostate diseases. According to several studies, high-risk human papillomaviruses cause malignancy by interfering
with the apoptotic and inflammatory… More >
Open Access
REVIEW
Haojie Zhang1, Xiaohong Wang2,*, Yue Yu2, Zhenlin Yang3,*
Oncologie, Vol.24, No.2, pp. 247-259, 2022, DOI:10.32604/oncologie.2022.020993
Abstract Chemotherapy plays an important role in controlling cancer progression, but the long-term use of chemotherapeutic agents can lead to drug resistance and eventually treatment failure. Therefore, elucidation of the mechanism of drug resistance is the key to solve the problem of chemotherapy resistance. In recent years, exosomes
derived from tumor cells have received extensive attention from researchers. In this paper, we reviewed the role
and mechanism of exosome-mediated tumor drug resistance in recent years, summarized the related studies of
exosome and chemotherapy drug resistance, and focused on several different ways by which exosomes participate
in tumor drug resistance. It includes… More >
Open Access
ARTICLE
Dayu Tian1, Yang Shi1, Li Lei1, Xiangmin Qiu1, Tao Song2,*, Qianyin Li1,*
Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838
（This article belongs to this Special Issue: Cancer Immunotherapy)
Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related differentially expressed genes… More >
Open Access
ARTICLE
Xingjun Meng1,#, Zhihui Cao2,#, Renfeng Liu3,#, Kai Zheng4, Shuai Ding5, Yuefan Gu4, Yonghua Chen6, Jun Lv7, Ping Li8, Li Zhou9, Wenbo Wang10, Shiliang Ji11, Hui He12,*, Hui Yang9,*
Oncologie, Vol.24, No.2, pp. 283-294, 2022, DOI:10.32604/oncologie.2022.021259
Abstract It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumor
drug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studies
have reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serve
as a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumor
progression, we chose paclitaxel and… More >
Open Access
ARTICLE
Yang Chen1,#, Huan Wu2,#, Annan Jiao3, Jiabing Tong4, Jie Zhu5, Mei Zhang1, Zegeng Li4,*, Ping Li1,*
Oncologie, Vol.24, No.2, pp. 295-307, 2022, DOI:10.32604/oncologie.2022.022116
Abstract Objectives: Lung cancer is a common and malignant tumor in adults and ranks first in the incidence and mortality of the top five malignant tumors in China. Our previous studies have shown that QYSL prescription can
balance lung cancer mice Th1/Th2 and inhibit tumor cell immune escape. Here, we examined the effects of QYSL
on lung cancer associated macrophage and the potential associated mechanism. Methods: C57BL/6 mice were
injected with Lewis lung cancer cells and treated with QYSL. FACS, RT-PCR, and western blot were used to examined the effect of QYSL on tumor immune microenvironment. Results: We found QYSL inhibited… More >
Open Access
ARTICLE
Minxi Rong1, Yong Li1,*, Xiaoli Guo1,*, Tao Zong2, Zhiyuan Ma2, Penglei Li2
Oncologie, Vol.24, No.2, pp. 309-327, 2022, DOI:10.32604/oncologie.2022.021256
Abstract Objectives: The ERα biological activity prediction model is constructed by the compound molecular data of the
anti-breast cancer therapeutic target ERα and its biological activity data, which improves the screening efficiency
of anti-breast cancer drug candidates and saves the time and cost of drug development. Methods: In this paper,
Ridge model is used to screen out molecular descriptors with a high degree of influence on the biological activity
of Erα and divide datasets with different numbers of the molecular descriptors by screening results. Random
Forest (RF) is trained by Root Mean Square Error (RMSE) and Coefficient of determination (R2) to… More >
Open Access
ARTICLE
Yi Chen1,#, Liyun Huang1,#, Zuwu Wei1, Xiaoling Liu1, Lihong Chen1,2,*, Bin Wang1,2,*
Oncologie, Vol.24, No.2, pp. 329-340, 2022, DOI:10.32604/oncologie.2022.022521
Abstract Background: The effective method for predicting prognosis of ICC is still lack. This study aims to establish and
verify an effective prognostic nomogram model for intrahepatic cholangiocarcinoma (ICC) after partial hepatectomy. Materials and Methods: A nomogram model was developed in a cohort of 127 patients from January
2015 to December 2019. General clinical characteristics including preoperative physical examination data and
postoperative pathological features were obtained. The independent risk factors identified by univariate and multivariate COX proportional hazards regression models were used to construct nomogram model. Predictive accuracy and discriminative ability were determined using a concordance index and a calibration curve.… More >
Login
Register
Submit a Paper
Propose a Special lssue